3 terminated. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 3 |
| Phase 1 | 2 | Terminated 2 |
Follow TLC 388: new trials by email Literature Review of TLC 388 trials Research Report on TLC 388
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis Lipotecan - HepatoCellular Carcinoma, Portal Vein Tumor Thrombosis | Phase 1 / Phase 2 | Terminated | Taiwan Liposome Company | 1 | 2017-04-14 | 2018-11-06 |
| Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma Lipotecan - Hepatocellular Carcinoma | Phase 2 | Terminated | Taiwan Liposome Company | 29 | 2014-04-10 | 2019-02-26 |
| A Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma Lipotecan® (TLC388) - Carcinoma, Hepatocellular | Phase 1 / Phase 2 | Terminated | Taiwan Liposome Company | 3 | 2011-10-27 | 2018-08-21 |
Taiwan (3) · China (1)
Carl Brown, PhD (1) · Chen-Hsi Hsieh, MD (1) · Jacqueline Whang-Peng, MD (1) · Tsang-En Wa, MD (1) · Yee Chao, MD (1) · Yunlong Tseng (1)